Objective-To identify unsupervised anabolic steroid regimens used by athletes. Methods-100 athletes attending four gymnasia were surveyed using an anonymous self administered questionnaire. Results-Anabolic steroid doses ranged from 250 to 3200 mg per week and users combined different drugs to achieve these doses. Injectable and oral preparations were used in cycles lasting four to 12 weeks. Eighty six per cent of users admitted to the regular use of drugs other than steroids for various reasons, including additional anabolic effects, the minimisation of steroid related side effects, and withdrawal symptoms. Acne, striae, and gynaecomastia were the most commonly reported subjective side effects.
gymnasia were surveyed using an anonymous self administered questionnaire. Results-Anabolic steroid doses ranged from 250 to 3200 mg per week and users combined different drugs to achieve these doses. Injectable and oral preparations were used in cycles lasting four to 12 weeks. Eighty six per cent of users admitted to the regular use of drugs other than steroids for various reasons, including additional anabolic effects, the minimisation of steroid related side effects, and withdrawal symptoms. Acne, striae, and gynaecomastia were the most commonly reported subjective side effects.
Conclusions-Multiple steroids are combined in megadoses and self administered in a cyclical fashion. Polypharmacy is practised by over 80% of steroid users. Skeletal muscle hypertrophy along with acne, striae, and gynaecomastia are frequent physical signs associated with steroid use.
(BrJ Sports Med 1997;31:54-58) Keywords: anabolic steroids; drug regimens; polypharmacy; physical signs. Male steroid users Illicit drug use by the athletes in this study was not confined to anabolic steroids, and 86% admitted using other drugs for different reasons (table 4 ). This figure is greater than previous estimates,4 and indeed the use of certain drugs listed below has not previously been documented in athletes. These "steroid accessory" drugs can be grouped according to their desired effects. Non-steroid agents with anabolic properties include clenbutarol, growth hormone, and insulin. Clenbutarol is a 3, receptor agonist used by 70% of this group for its ability to stimulate protein deposition in skeletal muscle (so called "repartitioning agent"), and also for its thermogenic properties, which increase energy expenditure, thereby reducing body fat.'0 11 Growth hormone is taken by a smaller number of steroid users (12%), probably because of its high black market price. One competitive bodybuilder reported using subcutaneous injections of 2 IU daily, which costs around £400 per month. Insulin, for example 1-2 units with meals, was also being used by two competitors for a supposed anabolic effect.
It appears that the athletes in this sample used steroids as their primary anabolic agent, with clenbutarol, growth hormone, or insulin being used as secondary anabolic drugs.
Ephedrine is a 12 receptor agonist used medically as a bronchodilator and vasoconstrictor sympathomimetic during anaesthesia. Fifty seven per cent of the athletes in this sample used ephedrine as a stimulant to aid athletic performance, and also as a thermogenic fat reducing agent.
Anticatabolic agents are also used to provide anabolic-like effects. Aminoglutethimide (Orimeten), used by 3% of the sample, is a steroid antagonist which preferentially blocks corticosteroid pathways, shifting the testosterone to cortisol ratio in favour of anabolism. The parenteral analgesic nalbuphine (Nubain) was used by 6% to relieve musculoskeletal pain and for a proposed "stress reducing" anticatabolic action. As with all morphine derivatives, however, repeated administration may cause drug dependence. '2 Additional drugs are used before bodybuilding competitions to enhance skeletal muscle visibility. L-thyroxine (for example, 200 ,ug daily) may be used in the four to six weeks leading up to a contest to reduce the amount of subcutaneous body fat. Clenbutarol and ephedrine have thermogenic effects and are also used for this purpose. Diuretics (for example, frusemide 20-40 mg) alleviate steroid induced water retention on the day of competition. Esiclene (formebolone) is injected directly into a muscle belly, causing local inflammation and thereby temporarily increasing its size over a period of 24 to 48 hours.
Medication is also used to reduce side effects and minimise withdrawal symptoms associated with steroid use. The antioestrogen drug tamoxifen was used by 45% of the athletes in this sample to prevent or treat gynaecomastia. Human chorionic gonadotrophin (HCG) is used at the end of a steroid cycle to kick start suppressed endogenous testosterone production in an attempt to reduce withdrawal symptoms.
It is apparent that the use of certain drugs listed above for medically unsound reasons may be of more concern than the use of anabolic steroids. The unsupervised use of diuretics, insulin, thyroxine, clenbutarol, and nubain may precipitate a range of acute medical emergencies.
ADVERSE EFFECTS AND WITHDRAWAL SYMPTOMS
Numerous side effects have previously been associated with anabolic steroids, including liver enzyme derangement,2 altered serum lipids, hypertension,' clotting abnormalities, '4 prostatic hypertrophy,'5 and behavioural changes.' Such effects are reversible on cessation of drug use, but may not be obviously apparent to the steroid user. The athletes in this study, however, frequently noticed subjective side effects including acne (54%), gynaecomastia (34%), striae (34%), and testicular shrinkage (40%). Even though such symptoms are common, they are usually considered minor and acceptable to the steroid user. Only 12% denied any steroid induced side effects. The striae are usually sited in the deltopectoral and axillary regions (fig 2) . Case reports have also linked steroids with liver tumours,2 myocardial infarction,' cardiomegaly, ' 
